Herpes zoster and postherpetic neuralgia
Neuropathic pain · C8 · Reviewed by a board-certified pain physician on November 2, 2026
Bottom line
Prevent zoster with recombinant vaccine, then treat postherpetic neuralgia as localized neuropathic pain: topicals suit small areas and frail patients, and systemic drugs need renal dosing and anticholinergic caution.
Key points
- Allodynia is the signature finding. Pain from a stimulus that does not normally hurt, such as light touch on a healed dermatome, is allodynia; increased pain from a painful stimulus is hyperalgesia 1.
- Vaccinate after shingles, once it heals. CDC recommends two doses of recombinant zoster vaccine, 2–6 months apart, for immunocompetent adults 50 and older, whether or not they report prior zoster; there is no specific waiting period other than avoiding vaccination during an acute episode 2.
- Topicals fit localized pain. NeuPSIG 2025 ranks lidocaine 5% plasters and capsaicin as weak second-line options 3; its 2015 version allowed lidocaine first line in frail older patients 8. After falls, Beers advises avoiding antidepressants and antiepileptics unless safer alternatives are unavailable 7.
- Know the patch rules. Lidocaine 5%: no more than three patches at a time on intact skin, worn a maximum of 12 hours and then off for 12 4. Capsaicin 8% for postherpetic neuralgia: up to four systems for 60 minutes, no more often than every 3 months 5.
- Systemic first-line drugs need care. Gabapentinoids, SNRIs and TCAs are first-line for neuropathic pain 3. Pregabalin is renally dosed: up to 600 mg/day with normal clearance, 75–300 mg/day at CrCl 30–60 mL/min 6.
- Avoid strongly anticholinergic TCAs in older adults. Beers lists amitriptyline among antidepressants to avoid because it is highly anticholinergic, sedating and causes orthostatic hypotension 7.
Watch for
High-yield for the exam
- Recombinant zoster vaccine is a two-dose series given 2–6 months apart 2.
- A prior zoster episode is not a reason to skip or delay vaccination once healed 2.
- Lidocaine patch absorption rises with treated area and wear time 4.
- Capsaicin 8% reduces TRPV1-expressing nerve endings, which re-emerge over months 5.
- Pregabalin at CrCl 15–30 mL/min: 25–150 mg/day; below 15: 25–75 mg/day 6.
- NeuPSIG 2025: capsaicin 8% patches, capsaicin cream and lidocaine 5% plasters are weak second-line options; lidocaine evidence is very low certainty 3.
- Hyperpathia is an abnormally painful, often explosive reaction, especially to repeated stimulation 1.
- Capsaicin 8% must not be applied to broken skin; staff wear nitrile gloves during application 5.
Numbers to know
Common traps
Practise this topic
5 more questions on this topic in the full question bank, with explanations and sources.
Sources
- IASP Terminology. International Association for the Study of Pain. iasp-pain.org/resources/terminology/
- Centers for Disease Control and Prevention. Shingles vaccine recommendations. CDC, 2024. cdc.gov/shingles/hcp/vaccine-considerations
- Soliman N, et al. Pharmacotherapy and non-invasive neuromodulation for neuropathic pain: a systematic review and meta-analysis. Lancet Neurol, 2025. pubmed.ncbi.nlm.nih.gov/40252663/
- US Food and Drug Administration. LIDODERM (lidocaine patch 5%) prescribing information. DailyMed, 2023. dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=db0092f5-02
- US Food and Drug Administration. QUTENZA (capsaicin) 8% topical system prescribing information. DailyMed, accessed 2026. dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3ffbbcb0-ad
- US Food and Drug Administration. LYRICA (pregabalin) prescribing information. DailyMed, accessed 2026. dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=60185c88-ec
- By the 2023 American Geriatrics Society Beers Criteria Update Expert Panel. American Geriatrics Society 2023 updated AGS Beers Criteria for potentially inappropriate medication use in older adults. J Am Geriatr Soc, 2023. pmc.ncbi.nlm.nih.gov/articles/PMC12478568/
- Finnerup NB, et al. Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis. Lancet Neurol, 2015. pmc.ncbi.nlm.nih.gov/articles/PMC4493167/
Related topics
Independent study material for the ABA Pain Medicine exam, written and reviewed by a board-certified pain physician. Not medical advice; not affiliated with the American Board of Anesthesiology.